Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Safety Dermatological Evaluation: Acceptability With Gynecological Follow up - Dermacyd Delicata Pocket BR
- Conditions
- Hygiene
- Interventions
- Drug: Lactic acid (Dermacid)
- First Posted Date
- 2008-04-22
- Last Posted Date
- 2009-01-29
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 30
- Registration Number
- NCT00663390
- Locations
- 🇧🇷
Sanofi-aventis, São Paulo, Brazil
Safety Dermatological Evaluation: Acceptability With Gynecological Follow up - Dermacyd Tina Gel Sweet Flower
- Conditions
- Hygiene
- Interventions
- Drug: Lactic acid (Dermacid)
- First Posted Date
- 2008-04-22
- Last Posted Date
- 2009-01-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 30
- Registration Number
- NCT00663325
- Locations
- 🇧🇷
Sanofi-aventis, São Paulo, Brazil
Safety Dermatological Evaluation: Acceptability With Gynecological Follow up - Dermacyd Tina Gel Sweet Flower
- Conditions
- Hygiene
- Interventions
- Drug: Lactic acid (Dermacid)
- First Posted Date
- 2008-04-22
- Last Posted Date
- 2009-01-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 30
- Registration Number
- NCT00663273
- Locations
- 🇧🇷
Sanofi-aventis, São Paulo, Brazil
Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended Vaccine
- Conditions
- DiphtheriaTetanusWhooping CoughPolioHaemophilus Influenzae Type b
- Interventions
- Biological: DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine)
- First Posted Date
- 2008-04-21
- Last Posted Date
- 2012-01-31
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1941
- Registration Number
- NCT00662870
Comparison Safety and Efficacy of Basal Insulin Lantus® (Insulin Glargine) vs NPH Insulin in Combination With Oral Antidiabetic Drugs (OADs) in Patients With Diabetes Mellitus, Type 2 (DMT2)
- First Posted Date
- 2008-04-16
- Last Posted Date
- 2010-07-30
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 117
- Registration Number
- NCT00659477
- Locations
- 🇨🇿
Sanofi-Aventis Administrative Office, Praha, Czech Republic
Effect of Insulin Glargine in Insulin Naïve Subjects With Type 2 Diabetes on Oral Hypoglycemic Agent(s)
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2008-04-04
- Last Posted Date
- 2009-04-20
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 764
- Registration Number
- NCT00653341
- Locations
- 🇨🇦
Sanofi-aventis administrative office, Laval, Canada
Phenotype Evaluation in Insulin Naive Patients Using Lantus (Insulin Glargine)
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2008-04-04
- Last Posted Date
- 2008-12-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 280
- Registration Number
- NCT00653302
- Locations
- 🇫🇷
Sanofi-aventis administrative office, Paris, France
Fasturtec TLS Treatment / Prophylysis
- Conditions
- Tumor Lysis Syndrome
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2008-04-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 45
- Registration Number
- NCT00651911
- Locations
- 🇺🇸
Sanofi-Aventis, Bridgewater, New Jersey, United States
Effect of Plavix on NO (Nitrogen Monoxide) Production of the Endothelial Function
- Conditions
- Peripheral Arterial Disease
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2008-04-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 39
- Registration Number
- NCT00648453
- Locations
- 🇭🇺
Sanofi-Aventis, Budapest, Hungary
Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell Lymphoma
- First Posted Date
- 2008-03-26
- Last Posted Date
- 2016-05-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 25
- Registration Number
- NCT00644124
- Locations
- 🇫🇷
Sanofi-Aventis Administrative Office, Paris, France